Research areas
GEMAC has several R&D projects focusing on
the areas of :
- neurosciences: development
of antibodies for a better understanding of
neuropathologies.
- immunology: identification
of biomarkers specific to autoimmune or degenerative
pathologies.
These studies are performed in collaboration
with well known clinicians worldwide.
New diseases targets
Based on the same technology as GEM-RR, GEM-SP
and GEM-ALS, other preclinical studies will be
launched on various neurological and auto-immune
diseases.
Development of idiotypic and anti-idiotypics
antibodies
GEMAC is expert in the development of idiotypic
antibodies (antibodies of first generation) but
also in the development of anti-idiotypic antibodies
(antibodies of second generation).
Major applications of the anti-idiotypic antibodies
are:
- immunoanalysis (when the ligand is very difficult
to handle).
- therapeutic field. An anti-idiotypic antibody
acts like a vaccine (if the causal factor is
bacterial, viral, ...) or like an analogue,
standing for the toxic ligand.
|
